Compare Adaptive Biotechnologies Corp (ADPT) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Canadian Natural Resources Ltd. — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while Canadian Natural Resources Ltd. trades at $47.81 (market cap $98.11B). The key difference: Canadian Natural Resources Ltd. is far larger — about 24.3× Adaptive Biotechnologies Corp's market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CNQ | |
|---|---|---|
Market Cap | $4.04B | $98.11B |
Sector | Health | Energy |
52-Week High | $25.45 | $50.55 |
52-Week Low | $12.30 | $29.31 |
Enterprise Value | $4.10B | $108.54B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Canadian Natural Resources (CNQ) trades at $47.845, up 1.26% today, with a bullish technical signal and strong earnings momentum after Q2 2026 EPS beat estimates. The company shows robust profitability with a 22.87% net margin and 26.69% ROE, supported by record production and disciplined capital spending. Recent news highlights dividend reliability and operational strength, with analyst consensus heavily favoring buy ratings.
CNQ presents a compelling investment case with attractive valuation (P/E 11.82), consistent dividend payouts, and positive cash flow trends. Key risks include oil price volatility and rising debt levels, but the company's scale and efficiency underpin resilience. Wall Street optimism, with 27 buy ratings, suggests further upside potential amid stable energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
